EQS-News: Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
- Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
The issuer is solely responsible for the content of this announcement. - Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally. - The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug's effectiveness and safety for patients.
- With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.